Vusolimogene Oderparepvec is named as an intervention in 3 current clinical trials in our USA, Germany, France, Spain, UK, Poland, Italy, Canada and Australia registers. 1 is recruiting patients now. The most common phase is Phase 2. The lead sponsor is Replimune, Inc. The most-studied condition is Advanced Melanoma.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
NCT06264180 · Advanced Melanoma
|
Phase 3 | Recruiting | Replimune, Inc | UK, USA, Germany, France, Spain, Poland |
|
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
NCT03767348 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC)
|
Phase 2 | Active, closed | Replimune, Inc | UK, USA, Germany, France, Spain |
|
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
NCT04050436 · ClinicalTrials.gov ↗ · Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
|
Phase 2 | Active, closed | Replimune, Inc | USA, Germany, France, Spain, Italy, Poland, Canada, Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Replimune, Inc | 3 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our USA, Germany, France, Spain, UK, Poland, Italy, Canada and Australia registers name Vusolimogene Oderparepvec (also registered as RP1) as a drug or biological intervention, as of the registry sync on 28 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 3 trials is recruiting: 1 with sites in USA, 1 with sites in Germany, 1 with sites in France, 1 with sites in Spain, 1 with sites in UK and 1 with sites in Poland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Replimune, Inc. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Vusolimogene Oderparepvec works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Vusolimogene Oderparepvec works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Vusolimogene Oderparepvec (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 28 Sep 2026.